Sigma Planning Corp Makes New Investment in uniQure N.V. $QURE

Sigma Planning Corp bought a new stake in uniQure N.V. (NASDAQ:QURE) in the 1st quarter, HoldingsChannel reports. The firm bought 16,900 shares of the biotechnology company’s stock, valued at approximately $276,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. CIBC Private Wealth Group LLC purchased a new position in shares of uniQure during the 3rd quarter worth $50,000. Torren Management LLC acquired a new position in shares of uniQure during the 4th quarter valued at about $28,000. IFP Advisors Inc purchased a new stake in shares of uniQure in the fourth quarter valued at about $48,000. Smartleaf Asset Management LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $48,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 906 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other uniQure news, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the transaction, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the transaction, the insider owned 169,669 shares in the company, valued at $4,251,905.14. This trade represents a 20.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 433,229 shares of company stock worth $17,944,799 in the last three months. 4.65% of the stock is currently owned by corporate insiders.

uniQure Stock Up 0.7%

Shares of QURE opened at $40.38 on Thursday. The company’s 50-day moving average price is $35.47 and its 200 day moving average price is $25.46. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a market cap of $2.55 billion, a P/E ratio of -11.60 and a beta of 0.90.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, sell-side analysts forecast that uniQure N.V. will post -3.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. HC Wainwright lifted their target price on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Leerink Partners increased their price target on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a report on Tuesday, May 5th. Finally, Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $25.00 to $65.00 in a research report on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.